DYAX CORP (DYAX) [Rocket]

Date Filed	Type	Description
07/20/2011	BW	Dyax Corp. to Host Second Quarter 2011 Earnings Call and Webcast
06/07/2011	BW	Dyax Corp. Announces Expansion of Executive Roles
06/01/2011	BW	Dyax Corp. to Present at the Jefferies Global Healthcare Conference
05/31/2011	BW	Dyax and Sigma-Tau Group Expand Agreement for KALBITOR® (ecallantide) in Hereditary Angioedema
05/18/2011	BW	Dyax Corp. to Present at the UBS Global Specialty Pharmaceuticals Conference
05/11/2011	BW	U.S. Patent Office Grants Dyax Corp.'s Request for an Interference with U.S. Patent No. 7,700,302 Issued to Adimab
04/29/2011	BW	Dyax Corp. to Present at the Deutsche Bank Health Care Conference
04/26/2011	BW	Dyax Corp. and Five Prime Therapeutics, Inc. Enter Into Research Agreement for Discovery of Therapeutic Antibodies
04/20/2011	BW	Dyax Corp. to Host First Quarter 2011 Earnings Call and Webcast
03/30/2011	BW	Dyax Corp. to Present at the Needham & Company Healthcare Conference
03/01/2011	BW	Dyax Corp. to Participate in March 2011 Healthcare Conferences
02/23/2011	BW	Dyax Corp. Announces Fourth Quarter and Full Year 2010 Financial Results
02/16/2011	BW	Dyax Corp. to Host Fourth Quarter and Year End 2010 Earnings Call and Webcast
11/14/2010	BW	KALBITOR® (ecallantide) Data Presented at the American College of Allergy, Asthma and Immunology Annual Meeting
10/27/2010	BW	Dyax Corp. Announces Third Quarter 2010 Financial Results
10/20/2010	BW	Dyax Corp. to Host Third Quarter 2010 Earnings Call and Webcast
10/20/2010	BW	Dyax Corp. to Host Third Quarter 2010 Earnings Call and Webcast
09/30/2010	BW	Dyax and CMIC Co., Ltd. Announce Partnership to Develop and Commercialize Subcutaneous DX-88 (ecallantide) for Hereditary Angioedema and Other Indications in Japan
07/28/2010	BW	Dyax Corp. Announces Second Quarter 2010 Financial Results
07/21/2010	BW	Dyax Corp. to Host Second Quarter 2010 Earnings Call and Webcast
07/19/2010	BW	Dyax Features Comprehensive Financial Assistance Program On Enhanced Product Website for KALBITOR® (ecallantide)
06/21/2010	BW	Dyax and Sigma-Tau Announce Partnership to Develop and Commercialize Subcutaneous DX-88 (ecallantide) for Hereditary Angioedema and Other Indications in Europe, North Africa, Middle East and Russia
05/10/2010	BW	Dyax Corp. to Present at the Rodman & Renshaw Annual Global Investment Conference
04/28/2010	BW	Dyax Corp. Announces First Quarter 2010 Financial Results
04/21/2010	BW	Dyax Corp. to Host First Quarter 2010 Earnings Call and Webcast
04/20/2010	BW	Dyax Corp. Sells Rights to Xyntha® Royalty Stream to Paul Capital Healthcare for up to $12 Million
04/05/2010	BW	Dyax Announces Underwriter's Exercise of Over-allotment Option
04/05/2010	BW	Dyax Corp. to Present at the 2010 Future Leaders in the Biotech Industry Conference
04/05/2010	BW	First-Ever Published Study Underscores Significant Economic Burden of Hereditary Angioedema on Patients, Families and the Healthcare System
03/25/2010	BW	Dyax Announces Pricing of Public Offering of Common Stock
03/24/2010	BW	Dyax Announces Proposed Public Offering of Common Stock
03/02/2010	BW	KALBITOR® (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology Annual Meeting
02/24/2010	BW	Dyax Corp. to Present at the Cowen and Company Health Care Conference
02/17/2010	BW	Dyax Corp. Announces Fourth Quarter and Year End 2009 Financial Results